Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Merck, Roche Sign Promotion Agreement

By Drug Discovery Trends Editor | July 21, 2011

TRENTON, N.J. (AP) – Merck & Co. and Roche Holding AG, formerly bitter rivals in the hepatitis C drug market, have expanded their recent collaboration to jointly promote their drugs.

The companies said that their subsidiaries have signed a new nonexclusive agreement to promote Merck’s new drug, Victrelis, worldwide as part of a triple-combination therapy, the new standard for fighting the sometimes-deadly disease.

Merck, based in Whitehouse Station, N.J., and Roche, headquartered in Switzerland, agreed in May to have their salespeople promote Victrelis along with the two companies’ older hepatitis C drugs. That deal came just days after Victrelis, one of two drugs in a new class expected to transform treatment of the tough-to-cure virus, was approved for sale in the U.S.

On Monday, Victrelis was approved for sale in all 27 European Union countries. Under the new agreement, Roche and Merck salespeople will work in markets including Europe, Asia and Latin America to educate physicians and patients about hepatitis C.

Roche sales reps will promote Victrelis along with Roche’s injected hepatitis C drug, Pegasys, and ribavirin pills. Merck salespeople will promote Victrelis plus its similar injected drug, PEG-Intron, and ribavirin. Ribavirin is available as a generic as well as Merck’s brand, Rebetol, and Roche’s brand, Copegus.

Victrelis and Incivek, approved in late May, are hepatitis C virus protease inhibitors, which block an enzyme needed for the blood-borne virus to copy itself. They’re the first new breakthrough treatments for the liver disease in 20 years. Incivek was developed by Vertex Pharmaceuticals Inc. and will be marketed outside the U.S. by Vertex partner Johnson & Johnson.

The two new drugs will cost roughly $50,000 per treatment, so they are likely to generate billions of dollars in annual sales – and a big battle for market share. Merck was first to market, but the Vertex drug is seen as slightly more effective, with studies suggesting Incivek cures about 80 percent of patients, versus 66 percent for Victrelis.

That’s far better than the typical 40 percent cure rate for what was the mainstay treatment, Copegus or Pegasys with ribavirin. Those drugs can cause nausea, anemia and fatigue for months, and ribavirin can damage or kill a fetus.

Roughly 4 million Americans have hepatitis C, many of them undiagnosed. It can cause liver damage, cirrhosis, liver failure or cancer.

Date: July 20, 2011
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE